HK Stock Market Move | EVEREST MED (01952) has risen more than 3% after recently releasing the first human data of the mRNA tumor vaccine EVM16. The company's RNA platform has been further validated.

Everest Med (01952) rose more than 3%, as of the press release, it rose by 3.48% to 31.48 Hong Kong dollars, with a turnover of 133 million Hong Kong dollars. On the news front, Everest Med recently announced that the company will present the first human clinical trial (FIH) data of the self-developed mRNA personalized tumor therapy vaccine EVM16 as monotherapy and in combination with PD-1 inhibitors (tislelizumab) for the treatment of advanced solid tumors at the 2026 American Association for Cancer Research (AACR) annual meeting. The founder pointed out that in the RNA platform, the off-the-shelf TAA mRNA vaccine EVM14 has received IND approval for new drug clinical trials in China and the United States and completed the first patient dosing; the mRNA autologous CAR-T project EVM18 has completed concept validation in non-human primates and advanced clinical development. In terms of self-development, the company will announce detailed clinical study data of EVER001 (BTK) in phase 1b/2a in the first half of 2026.